Organization
University of Washington School of Medicine and Fred Hutchinson Cancer Center
7 abstracts
Abstract
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Org: Winship Cancer Institute of Emory University, IRCCS Ospedale San Raffaele, Sarah Cannon Research Institute/Tennessee Oncology, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group,
Abstract
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.Org: Sarah Cannon Research Institute/Tennessee Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.Org: Baylor University Medical Center, Texas Oncology, The US Oncology Network, International Breast Cancer Center (IBCC), Quironsalud Group,
Abstract
Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results.Org: Los Angeles Cancer Network, Inova Schar Cancer Institute, Northwest Medical Specialties, Virginia Oncology Associates, Valkyrie Clinical Trials, Inc,
Abstract
Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.Org: Memorial Sloan Kettering Cancer Center, University of Washington School of Medicine and Fred Hutchinson Cancer Center, University of Pittsburgh, Washington University School of Medicine, Kaplan Hospital,
Abstract
Study of the Bria-IMT regimen and CPI vs physicians' choice in advanced metastatic breast cancer (BRIA-ABC).Org: University of Washington School of Medicine and Fred Hutchinson Cancer Center, Mayo Clinic Florida, University of Pittsburgh, Hoag Cancer Center, Newport Beach, CA, Morehouse School of Medicine,